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OBJECTIVE: To investigate the antifibrotic effects of crocetin in scleroderma fibroblasts and in sclerotic mice.
METHODS: Skin fibroblasts that were isolated from three systemic scleroderma (SSc) patients and three healthy
subjects were treated with crocetin (0.1, 1 or 10 mM). Cell proliferation was measured with an MTT assay. Alpha-
smooth muscle actin was detected via an immunohistochemical method. Alpha 1 (I) procollagen (COL1A1),
alpha 1 (III) procollagen (COL3A1), matrix metalloproteinase (MMP)-1 and tissue inhibitor of matrix
metalloproteinase (TIMP)-1 mRNA levels were measured using real-time PCR. SSc mice were established by
the subcutaneous injection of bleomycin. Crocetin (50 mg/kg/d) was injected intraperitoneally for 14 days.
Dermal thickness and lung fibrosis were assessed with Masson’s trichrome staining. Plasma ET-1 was detected
with an enzyme-linked immunosorbent assay (ELISA). Skin and lung ET-1 and COL1A1 mRNA levels were
measured via real-time PCR.
RESULTS: Crocetin inhibited the proliferation of SSc and normal fibroblasts, an effect that increased with
crocetin concentration and incubation time. Crocetin decreased the expression of a-SMA and the levels of
mRNA for COL1A1, COL3A1 and matrix metalloproteinase-1, while crocetin increased TIMP-1 mRNA levels in
both SSc and normal fibroblasts. Skin and lung fibrosis was induced, and the levels of ET-1 in the plasma, skin
and lungs were elevated in bleomycin-injected mice. Crocetin alleviated the thickening of the dermis and lung
fibrosis; decreased COL1A1 mRNA levels in the skin and lung; and simultaneously decreased ET-1 concentrations
in the plasma and ET-1 mRNA levels in the skin and lungs of the bleomycin-induced sclerotic mice, especially
during the early phase (weeks 1-3).
CONCLUSION: Crocetin inhibits cell proliferation, differentiation and collagen production in SSc fibroblasts.
Crocetin alleviates skin and lung fibrosis in a bleomycin-induced SSc mouse model, in part due to a reduction in
ET-1.
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& INTRODUCTION
Systemic scleroderma (SSc) is a complex, chronic con-
nective tissue disease that has three cardinal clinical
features: the excessive deposition of extracellular matrix
(ECM), vascular damage and inflammation/autoimmunity
(1). Despite an unclear pathogenesis, SSc is characterized by
the pathologic remodeling of the connective tissues in the
skin and internal organs, which is due to the overproduc-
tion of ECM, especially the production of collagen by
fibroblasts (2). Therefore, many of the landmark in vitro SSc
studies were based on the study of cultured fibroblasts.
Regarding in vivo research, the bleomycin-induced experi-
mental sclerotic mouse is a good model for studying the
prevention or treatment of fibrosis and is the most
frequently used model (3). However, there is currently still
no cure for SSc and little possibility of modifying or
reversing the fibrosis of the skin and internal organs.
Saffron, a spice and food colorant present in the dry
stigmas of the plant Crocus sativus L., has been used as an
herbal remedy for various ailments, including cancer, in the
ancient Arabian, Indian and Chinese cultures. Crocetin, an
important carotenoid constituent of saffron, has shown
significant potential as an anti-tumor agent in animal
models and cell culture systems (4). This unique carotenoid
contains a short carbon chain length (C20 apocarotenoid)
and carboxyl groups at both ends of the carbon chain (5).
Additionally, crocetin exhibits other pharmacological
actions, including the inhibition of retinal ischemic damage
in mice (6) and neuroprotection in conjunction with
selenium in cognitive impairment (7). More intriguingly,
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recent research has revealed that crocetin reverses cardiac
hypertrophy in vivo and inhibits the collagen synthesis that
is stimulated by angiotensin (Ang) II in cardiac fibroblasts
(8). Because the pathogenic processes of SSc and cardiac
hypertrophy share many similar features, we became
interested in whether crocetin has an effect on SSc.
In this study, we investigated the possible antifibrotic
effects of crocetin in vitro in fibroblasts isolated from
patients with SSc and in vivo in bleomycin-induced sclerotic
mice. This study contributes to the potential use of crocetin
as a treatment for fibrosis in SSc patients.
& MATERIALS AND METHODS
Cell culture and crocetin treatment
Skin biopsies were obtained from three patients who met
the American College of Rheumatology criteria for SSc(9)
(with a less than 1-year duration of the disease) and were not
undergoing treatment and from three age- and sex-matched
healthy subjects. Full-thickness 7-mm biopsies that were
50 mm2 in size were excised from the forearm lesions of the
patients with SSc and from the healthy controls. Primary
cultures of the skin fibroblasts were established using the
method introduced by Zhu et al. (10). The fibroblasts were
serially passaged in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS) (PAA,
Pasching, Austria) in an incubator at 37 C˚ with 5% CO2. The
cells were used for the crocetin administration experiments at
passages 3 to 6 at early confluence. The study protocol was
reviewed and approved by the research ethics committee of
Zhongshan Hospital, and informed consent was obtained
from all of the participants. In the following assays, after
reaching 90% confluency, the fibroblasts were synchronized
by serum starvation for 24 h. The fibroblasts were then
treated for 24 h in serum-free culture medium (except for the
MTT assay) with crocetin (0.1, 1 or 10 mM, ChromaDex,
USA). The crocetin was dissolved in dimethylsulfoxide
(DMSO, Sigma, USA) for all of the in vitro studies. The
above concentrations are commonly employed in in vitro
studies (8) and caused no apparent cell toxicity in our
preliminary assay. Untreated cells in the same medium were
used as controls.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
For the MTT assay, the fibroblasts were seeded into 96-
well microplates (26103 cells/well) in triplicate. After
incubation with crocetin (0.1, 1 or 10 mM) in DMEM
containing 2% FBS for 1, 3 or 6 days (with a change of the
culture media on the fourth day), an MTT solution
(Amresco, USA) at a final concentration of 0.5 g/L was
added, and the clones were further incubated at 37 C˚ for
4 h. The cells were then solubilized in 1 ml of 10% DMSO
(Sigma, USA) for 10 min. Finally, the absorbance at 570 nm
was measured with a microplate reader (Bio-Rad, USA).
Immunohistochemistry
To measure a-smooth muscle actin (a-SMA), sterile
microscope coverslips (Fisher, USA) were placed into the
individual wells of 24-well cell culture plates, and the
fibroblasts from the SSc patients or the healthy controls
were incubated on the coverslips at a concentration of
16105 cells/cm2. After reaching 90% cell confluency, the
cells were treated with crocetin. The cell-containing cover
slips were blocked with 5% BSA and then incubated
overnight at 4 C˚ with an a-SMA mouse monoclonal antibody
(Boster, China). The visualization of antibody staining was
performed according to the manufacturer’s instructions for
the 3,3’-Diaminobenzidine (DAB) Horseradish Peroxidase
Color Development Kit (Boster, China). The staining wasre-
peated for each sample at least three times, and photomicro-
graphs were obtained with a microscope (Olympus, Japan).
At minimum, 30 cells in several microscopic fields in each
slide at6400 magnification were scored by two independent
examiners. The ratio of positive cells/total number of cells
counted was calculated.
Detection of COL1A1, COL3A1, MMP-1 and TIMP-1
mRNA levels by real-time PCR
After incubation with crocetin (0.1, 1 or 10 mM) for 24 h,
total RNA from the fibroblasts was isolated with TRIzol
(Invitrogen, USA) and was reverse-transcribed to generate
cDNA. COL1A1, COL3A1, MMP-1 and TIMP-1 mRNA
levels in the fibroblasts were detected via real-time RT-PCR,
which was performed using a SYBR Green Master Mix
(TaKaRa, Japan) at 95 C˚ for 30 s, followed by 40 cycles of
95 C˚ for 5 s and 60 C˚ for 20 s. GAPDH was used as an
internal control. The primers that were used are shown in
Table 1. A relative quantification was performed using the
2-DDCt method (11,12). The experiments were performed in
triplicate and were repeated twice.
Induction of dermal and lung sclerosis in mice and
the administration of crocetin
Female C3H/He mice, aged 6 weeks and weighing 20 to
25 g, were obtained from Vitalriver Laboratory Animal
Center (Beijing, China) and were maintained under patho-
gen-free conditions. The animal protocol was approved
by the Committee of Animal Care and Use of Fudan
University. Bleomycin powder (Nihon Kayaku, Tokyo,
Japan) was dissolved in phosphate-buffered saline (PBS;
0.01 M, pH 7.4) at a concentration of 0.2 g/L. A crocetin
suspension was prepared using a 0.5% carboxymethylcellu-
lose (CMC) solution for the animal experiments. For the SSc
mouse model, 100 ml of filter-sterilized bleomycin or PBS
was subcutaneously injected into the shaved backs of
the mice daily for 3 weeks with a 27-gauge needle.
Simultaneously, either vehicle (CMC) or crocetin (50 mg/
Table 1 - List of primers used for real-time PCR.
Sample/control gene Primer Sequence (5’-3’)
Homo MMP-1 TGAAAAGCGGAGAAATAGTGG
GAGGACAAACTGAGCCACATC
Homo TIMP-1 ATACTTCCACAGGTCCCACAAC
GGATGGATAAACAGGGAAACAC
Homo COL1A1 CCTGGAAAGAATGGAGATGATG
ATCCAAACCACTGAAACCTCTG
Homo COL3A1 GCTGGCTACTTCTCGCTCTG
TCCGCATAGGACTGACCAAG
Homo GAPDH GGTGAAGGTCGGTGTGAACG
CTCGCTCCTGGAAGATGGTG
Mus ET-1 GACCAGACACCGTCCTCTTC
TGGAAAGTCACGAACAGCAG
Mus COL1A1 GGTCTTGGTGGTTTTGTATTCG
AACAGTCGCTTCACCTACAGC
Mus GAPDH CCCCTTCATTGACCTCAACTAC
GAGTCCTTCCAGGATACCAAAG
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kg/d) was injected intraperitoneally for 14 days into the
mice that were injected subcutaneously with bleomycin.
The concentration of crocetin used in these experiments
had previously exhibited maximal efficacy in suppressing
cardiac hypertrophy without apparent cell toxicity in mice
(8). At the end of week 1 (W1), W2, W3, W5 and W7 after
bleomycin/PBS injection, the mice (six per group per time
point) were euthanized by CO2 asphyxiation, and periph-
eral blood plasma samples were taken by cardiac puncture
and centrifuged at 4 C˚. The back skins and lungs were
collected for histological examination or were snap-frozen
in liquid nitrogen.
Histological evaluation of skin and lung tissues
Formalin-fixed skin and lung tissues were paraffin-
embedded and stained with hematoxylin and eosin and
Masson’s trichrome stain. The sections were examined
using a Leica DFC 280 light microscope. Five randomly
selected sites in two Masson’s trichrome-stained skin or
lung sections from each mouse were examined at 6100
magnification. Using a Leica Q Win Plus Image Analysis
System (Leica Micros Imaging Solutions Ltd., Cambridge,
UK), the dermal thickness (measured from the epidermal–
dermal junction to the dermal–fat junction) was determined.
The percentage of lung tissue fibrosis was evaluated by
counting the number of pixels corresponding to the stained
collagen areas.
Plasma endothelin-1 (ET-1) concentration detected
with an enzyme linked immunosorbent assay
(ELISA)
Peripheral blood plasma ET-1 concentrations were mea-
sured according to the manufacturer’s protocol with an
ELISA kit (USCN, Wuhan, China). The absorbance at
570 nm was measured using a microplate reader (Bio-Rad,
USA). The experiments were performed in triplicate and
were repeated twice.
Skin and lung ET-1 and COL1A1 mRNA expression
detected by real-time PCR
The skin and lung ET-1 and COL1A1 mRNA levels in the
mice were detected via real-time PCR as described above.
The primer pairs that were used are shown in Table 1. The
experiments were performed in triplicate and were repeated
twice.
Statistics
All of the statistical analyses were performed using SPSS
13.0 software. The quantitative data were expressed as the
means ¡ SEM. The quantitative variables were compared
using the two-sample Student’s t-test or a one-way
ANOVA. Statistical significance was defined as p,0.05.
& RESULTS
Inhibitory effect of crocetin on fibroblast
proliferation
On D1, D3 and D6, crocetin inhibited fibroblast prolifera-
tion derived from both SSc patients and healthy individuals
compared to the untreated control fibroblasts. Moreover,
this inhibitory effect increased with concentration and
incubation time (Figures 1A and 1B).
Effect of crocetin on COL1A1, COL3A1, MMP-1 and
TIMP-1 mRNA levels in fibroblasts
Compared to normal fibroblasts, the levels of COL1A1,
COL3A1 and TIMP-1 mRNAs in the SSc fibroblasts
increased significantly (p,0.05 or p,0.01), while there was
no difference in MMP-1 mRNA levels between the SSc and
normal fibroblasts (p.0.05). Crocetin decreased COL1A1
and COL3A1 mRNA levels in SSc and normal fibroblasts
(p,0.05 or p,0.01) in comparison with the untreated
controls (Figure 2A and 2B). Crocetin also decreased
MMP-1 mRNA levels in SSc and normal fibroblasts
(p,0.05 or p,0.01, Figure 2C). In contrast, crocetin increased
TIMP-1 mRNA levels in the fibroblasts at concentrations of
0.1 and 10 mM (p,0.05 or p,0.01, Figure 2D) with no
significant effect on TIMP-1 mRNA levels in the fibroblasts
at a concentration of 1 mM. However, among the three
concentrations used, crocetin at a concentration of 1 mM
resulted in the most significant inhibitory effect on the
expression of COL1A1, COL3A1, and MMP-1 mRNA levels.
Inhibitory effect of crocetin on a-SMA expression in
SSc and normal fibroblasts
a-SMA expression increased in SSc fibroblasts compared
to normal fibroblasts (p,0.05). All tested concentrations of
crocetin decreased a-SMA expression in both SSc and
normal fibroblasts (p,0.05 or p,0.01, Figure 3A-3D).
Crocetin at a concentration of 1 mM significantly decreased
a-SMA expression in SSc and normal fibroblasts compared
to the other two concentrations tested (p,0.05 or p,0.01,
Figure 3E).
Figure 1 - Inhibitory effect of crocetin on the proliferation of
fibroblasts derived from SSc patients and healthy individuals.
Fibroblast proliferation was detected with the MTT assay, and
absorbance at 570 nm was measured. (A) Proliferation of SSc
fibroblasts. (B) Proliferation of normal fibroblasts.
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Antifibrotic effect of crocetin in bleomycin-induced
sclerotic mice
The histological examination of the skin and lung tissue
from the mice is shown in Figure 4A. The dermal thicknesses
and percentages of lung fibrosis in the bleomycin-injected
and the bleomycin+CMC-injected mice were significantly
higher than in the PBS- and bleomycin+crocetin-injected
mice, respectively (p,0.05, Figure 4B and 4C). The COL1A1
mRNA levels in the skin and lungs from the mice at different
time points are shown in Figure 4D and Figure 4E. The
Figure 2 - Effect of crocetin on COL1A1, COL3A1, MMP-1 and TIMP-1 mRNA expression in SSc and normal fibroblasts. mRNA expression
was detected using quantitative reverse transcription–polymerase chain reaction, and relative quantification was performed using the
2-DDCt method. The experiments were performed in triplicate and repeated twice. (A) COL1A1; (B) COL3A1; (C) MMP-1; (D) TIMP-1.
* p,0.05, ** p,0.01.
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bleomycin-injected mice had higher skin COL1A1 mRNA
levels than the PBS-injected mice, a difference that increased
with time. The bleomycin+crocetin-injected mice had lower
skin COL1A1 mRNA levels than the bleomycin+CMC-
injected mice. The bleomycin-injected mice had higher lung
COL1A1 mRNA levels than the PBS-injected mice, and the
bleomycin+CMC-injected mice had higher lung COL1A1
mRNA levels than the crocetin-injected mice at the end of
W1, W2 and W3.
Plasma ET-1 levels and ET-1 mRNA levels in mouse skin
and lungs
At W1, the bleomycin-injected mice had significantly
higher plasma ET-1 levels than the PBS-injected mice, and
the bleomycin+crocetin-injected mice had significantly lower
plasma ET-1 levels than the bleomycin+CMC-injected mice
(Figure 5A). Afterward, the differences between the
bleomycin- and PBS-injected mice and between the
bleomycin+CMC-injected and bleomycin+crocetin-injected
mice were not significant. The bleomycin-injected mice had
significantly higher skin ET-1 mRNA levels than the PBS-
injected mice after W1, W5 and W7. The bleomycin+crocetin-
injected mice had significantly lower skin ET-1 mRNA levels
than the bleomycin+CMC-injected mice (Figure 5B).
Afterward, the differences between the bleomycin-injected
and the PBS-injected mice and between the bleomycin+CMC-
injected and the bleomycin+crocetin-injected mice were not
significant. The bleomycin-injected mice had higher lung ET-
1 levels than the PBS-injected-mice at W1. Afterward, the
difference between the bleomycin-injected and the PBS-
injected mice was not significant. The bleomycin+crocetin-
injected mice had lower lung ET-1 levels than the
bleomycin+CMC-injected mice at the end of the W1
(Figure 5C).
& DISCUSSION
The most prominent clinical features of SSc are caused by
the excessive deposition of ECM components, especially
type I and type III collagen, in the skin and involved organs,
such as the lung. Type I collagen is composed of two alpha 1
(I) chains and one alpha 2 (I) chain that are expressed
coordinately in human fibroblasts (13,14). Type III collagen
is composed of two alpha 1 (III) chains(13). The upregulated
COL1A1 and COL3A1 genes in SSc fibroblasts play
important roles in the pathogenesis of SSc. MMP-1 promotes
the degradation of both type I and type III collagen, and
MMP-1 activity is inhibited by TIMP-1. Therefore, the
balance of MMP-1 and TIMP-1 maintains the homeostasis
of tissue damage and repair (15). Another marker of the
Figure 3 - Inhibitory effect of crocetin on the expression of a-smooth muscle actin (a-SMA) in SSc and normal fibroblasts. (A-D) a-SMA
expression in normal fibroblasts. Original magnification 6100. (a-SMA expression in SSc fibroblasts is not shown because the
appearance is similar to normal cells). (E) a-SMA positive cells/total number of cells counted (%). * p,0.05, ** p,0.01.
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activated SSc fibroblast is the expression of a-SMA. SSc
is associated with the differentiation of fibroblasts into
myofibroblasts, which is characterized by the expression of
a-SMA contractile filaments. Myofibroblasts present some
activation features, including high levels of ECM gene
expression, during normal reparative or pathological
fibrotic processes (16).
In vitro, we observed an inhibitory effect of crocetin on
the proliferation of both the SSc and normal fibroblasts, an
effect that increased with concentration and time. We also
observed crocetin-induced inhibition of a-SMA expression
in SSc fibroblasts. In addition, crocetin significantly
decreased COL1A1 and COL3A1 mRNA levels in both SSc
and normal fibroblasts. These findings indicate that crocetin
inhibits overproliferation, the overproduction of collagen
and the differentiation of fibroblasts, whether the fibroblasts
are derived from patients with SSc or from healthy
individuals. In addition, we noted that MMP-1 mRNA
levels in the fibroblasts decreased, while TIMP-1 mRNA
levels increased after treatment with crocetin. This observa-
tion suggests that crocetin may have dual effects on the
metabolism of collagen in fibroblasts, which involve
inhibiting both the production and the degradation of
collagen. Among the three concentrations of crocetin used in
nearly all of the in vitro assays, crocetin at 1 mM had the
most significant effect. This result indicates that 1 mM is
possibly one of the most suitable concentrations for study-
ing the effect of crocetin on cultured fibroblasts.
ET-1, an important endogenous peptide hormone that
potently promotes vasculopathy, inflammation and fibrosis,
is one of the most important pathogenic endogenous peptide
hormones in the pathogenesis of SSc(17). Furthermore,
elevated levels of circulating ET-1 in patients with SSc have
been observed (18,19). Therefore, elevated ET-1 may be an
indicator for disease activity in SSc. Our in vivo study
demonstrated that plasma ET-1 levels and ET-1 mRNA levels
Figure 4 - Histological evaluation of mouse skin and lung tissues. (A) Representative pathologic findings from the skin and lung tissue
from the mice at W3 after beginning the bleomycin or crocetin treatment;6100, Masson’s trichrome staining. (B) Dermal thickness
(measured from the epidermal–dermal junction to the dermal–fat junction). (C) Percentage of lung fibrosis (evaluated by counting the
numbers of pixels corresponding to stained collagen areas). (D) Skin COL1A1 mRNA levels; (E) Lung COL1A1 mRNA levels.
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Figure 5 - Plasma, skin and lung ET-1 levels in mice. (A) Plasma ET-1 levels; (B) skin ET-1 mRNA levels; (C) lung ET-1 mRNA levels. Plasma
ET-1 levels were detected using an ELISA. ET-1 mRNA expression was detected via a quantitative reverse transcription-polymerase chain
reaction, and relative quantification was performed using the 2-DDCt method.
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in the skin and lungs of bleomycin-induced sclerotic mice
were significantly higher than the levels found in the PBS-
injected mice at an early phase (1-3 weeks), which is similar to
previous results(20,21). Crocetin significantly reversed skin
thickening, lung fibrosis and COL1A1 mRNA levels in the
skin and lungs of bleomycin-induced sclerotic mice, espe-
cially within the early phase (1-3 weeks). Simultaneously,
crocetin decreased plasma ET-1 levels and ET-1 mRNA levels
in the skin and lungs of bleomycin-induced sclerotic mice,
especially within the early phase (1-3 weeks). Therefore, we
speculate that in addition to the direct antifibrotic effect, the
capacity of crocetin to alleviate bleomycin-induced fibrosis
may be caused, at least in part, by the reduction of ET-1 in the
plasma and fibrotic tissues of these mice.
Furthermore, some cytokines, such as interleukin-6 (IL-6)
and transforming growth factor b (TGF-b), are highly
involved in the pathogenesis of scleroderma (22). Crocetin
has been found to attenuate the expression of IL-6 in mice
(23), but whether this effect can be blocked by the addition
of IL-6 remains unknown. Nevertheless, little is known
regarding the effect of crocetin on other crucial cytokines,
such as TGF-b. These observations indicate the necessity to
further investigate the potential effect of crocetin on the
profibrotic cytokines in cultured SSc fibroblasts in vitro or in
the SSc experimental model in vivo.
In conclusion, our findings provide new evidence that
crocetin inhibits the overproliferation and differentiation of
SSc fibroblasts. In addition, crocetin may possess the dual
effects of inhibiting both the overproduction and the
degradation of collagen in fibroblasts. Furthermore, crocetin
reversed the skin and lung fibrosis that occurs in a
bleomycin-induced SSc mouse model, which may be due,
at least in part, to the reduction of ET-1 in the plasma and
fibrotic tissues of these mice. This study highlights the
potential use of crocetin as a new drug for the treatment of
fibrosis in patients with SSc.
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